secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2026-07-15T10:00:36+00:00
Accession:  0001193125-26-303948
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health reports positive one-year REMAIN-1 data: Revita maintains 81% of GLP-1 weight loss after discontinuation
--------------------------------------------------------------------------------

- Single Revita procedure reduced weight regain by ~40% vs sham at one year (7.8% vs 13.0% regain in mITT, N=45).
- Complete duodenal ablation (>14 cm) maintained ~81% of GLP-1-induced weight loss vs 48% sham (4.8% vs 13.0% regain).
- Optimized patients (≥17.5% run-in loss) maintained ~84% vs 46% (4.1% vs 13.5% regain); responder rate 73% mITT, 91% complete ablation.
- No device/procedure-related serious adverse events; TEAE rates comparable (24% Revita vs 25% sham).
- Next milestones: topline Pivotal Cohort data early Q4 2026; potential FDA De Novo submission late Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526303948/0001193125-26-303948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526303948/guts-20260715.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-303948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer